Maternal and Infant Health Care Costs Related to Preeclampsia

Hao, Jing; Hassen, Dina; Hao, Qiang; Graham, Jove; Paglia, Michael J.; Brown, Jason; Cooper, Matthew; Schlieder, Victoria; Snyder, Susan

doi:10.1097/aog.0000000000003581

Cited by 44 publications

(36 citation statements)

References 16 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypertensive disorders included both confirmed pre-eclampsia (one Irish and one US study [25,56]) and hypertension during pregnancy (three studies set in the US [30,37,56]), with all hypertension studies examining different costs (mothers only, children only or mother and children combined). Incremental costs per case for hypertension ranged from €2,860 to €8,595 (Table 4).…”

Section: Other Maternal Health Problemsmentioning

confidence: 99%

Economic burden of maternal morbidity – A systematic review of cost-of-illness studies

et al. 2020

View full text Add to dashboard Cite

To estimate the economic burden of common health problems associated with pregnancy and childbirth, such as incontinence, mental health problems, or gestational diabetes, excluding acute complications of labour or birth, or severe acute adverse maternal outcomes. Methods Searches for relevant studies were carried out to November 2019 in Medline, Embase, CINAHL, PsycINFO and EconLit databases. After initial screening, all results were reviewed for inclusion by two authors. An adapted version of a previously developed checklist for cost-of-illness studies was used for quality appraisal. All costs were converted to 2018 Euro using national consumer price indices and purchasing power parity conversion factors. Results Thirty-eight relevant studies were identified, some of which reported incremental costs for more than one health problem (16 gestational diabetes, 13 overweight/obesity, 8 mental health, 4 hypertensive disorders, 2 nausea and vomiting, 2 epilepsy, 1 intimate partner violence). A high level of heterogeneity was observed in both the methods used, and the incremental cost estimates obtained for each morbidity. Average incremental costs tended to be higher in studies that modelled a hypothetical cohort of women using data from a range of sources (compared to analyses of primary data), and in studies set in the United States. No studies that examined the economic burden of some common pregnancy-related morbidities, such as incontinence, pelvic girdle pain, or sexual health problems, were identified. Conclusion Our findings indicate that maternal morbidity is associated with significant costs to health systems and society, but large gaps remain in the evidence base for the economic burden of

show abstract

Section: Other Maternal Health Problemsmentioning

confidence: 99%

Economic burden of maternal morbidity – A systematic review of cost-of-illness studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although close monitoring of pregnancies affected by or at high risk of HDP is recommended, the extent at which these women are being monitored and managed is not well understood, considering the high rates of mortality in Brazil and other LMICs. No surveillance data exist for monitoring and reducing the impact of HDP in these countries, and the burden of families affected by these conditions [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study

Leal

Grandi

Miranda

et al. 2020

IJERPH

View full text Add to dashboard Cite

Hypertensive disorders of pregnancy account for approximately 22% of all maternal deaths in Latin America and the Caribbean. Pharmacotherapies play an important role in preventing and reducing the occurrence of adverse outcomes. However, the patterns of medications used for treating women with hypertensive disorders of pregnancy (HDP) living in this country is unclear. A population-based birth cohort study including 4262 women was conducted to describe the pattern of use of cardiovascular agents and acetylsalicylic acid between women with and without HDP in the 2015 Pelotas (Brazil) Birth Cohort. The prevalence of maternal and perinatal outcomes in this population was also assessed. HDP were classified according to Ministry of Health recommendations. Medications were defined using the Anatomical Therapeutic Chemical Classification System and the substance name. In this cohort, 1336 (31.3%) of women had HDP. Gestational hypertension was present in 636 (47.6%) women, 409 (30.6%) had chronic hypertension, 191 (14.3%) pre-eclampsia, and 89 (6.7%) pre-eclampsia superimposed on chronic hypertension. Approximately 70% of women with HDP reported not using any cardiovascular medications. Methyldopa in monotherapy was the most frequent treatment (16%), regardless of the type of HDP. Omega-3 was the medication most frequently reported by women without HDP. Preterm delivery, caesarean section, low birth weight, and neonatal intensive care admissions were more prevalent in women with HDP. Patterns of use of methyldopa were in-line with the Brazilian guidelines as the first-line therapy for HDP. However, the large number of women with HDP not using medications to manage HDP requires further investigation.

show abstract

“…Preeclampsia is a $2.18 billion (USD) per year problem, 23 and those pregnancies are 3 times more expensive than uncomplicated pregnancies, points we emphasized in an editorial and later studies confirmed. 24,25 As data from the MMRCs were reported in mainstream media, the court of public opinion helped fuel federal legislative efforts. The Foundation, working closely with partners (the ACOG, March of Dimes, Association of Maternal and Child Health Programs, and Society for Maternal-Fetal Medicine) and fueled by dozens of patient organizations, successfully shepherded the Preventing Maternal Deaths Act through a multiyear, bipartisan effort that President Trump signed into law in December 2018.…”

Section: Advocacymentioning

confidence: 99%

The Preeclampsia Foundation: the voice and views of the patient and her family

Tsigas

2022

American Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

Maternal and Infant Health Care Costs Related to Preeclampsia

Abstract: Brown J, et al. Maternal and infant health care costs related to preeclampsia. Obstet Gynecol 2019;134. The authors provided this information as a supplement to their article.

Cited by 44 publications

References 16 publications

Economic burden of maternal morbidity – A systematic review of cost-of-illness studies

Economic burden of maternal morbidity – A systematic review of cost-of-illness studies

Hypertensive Disorders of Pregnancy and Medication Use in the 2015 Pelotas (Brazil) Birth Cohort Study

The Preeclampsia Foundation: the voice and views of the patient and her family

Contact Info

Product

Resources

About